本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/11/101 分钟阅读
Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder
本地自动翻译 · 来源原始语言
摘要
SUZHOU, China and MÖLNDAL, Sweden, Nov. 10, 2026 — Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a…
来源原始语言: PR Newswire UK — News Releases打开原始公告 →